SLS vs. ELDN, NEOS, CLRB, MLND, CORV, DSGN, CRMD, MRSN, ZVRA, and ATAI
Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Eledon Pharmaceuticals (ELDN), Neos Therapeutics (NEOS), Cellectar Biosciences (CLRB), Millendo Therapeutics (MLND), Correvio Pharma (CORV), Design Therapeutics (DSGN), CorMedix (CRMD), Mersana Therapeutics (MRSN), Zevra Therapeutics (ZVRA), and Atai Life Sciences (ATAI). These companies are all part of the "medical" sector.
SELLAS Life Sciences Group (NASDAQ:SLS) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
SELLAS Life Sciences Group has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
SELLAS Life Sciences Group has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, SELLAS Life Sciences Group and SELLAS Life Sciences Group both had 3 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 0.96 beat SELLAS Life Sciences Group's score of 0.58 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.
SELLAS Life Sciences Group presently has a consensus target price of $3.00, suggesting a potential upside of 157.05%. Eledon Pharmaceuticals has a consensus target price of $11.67, suggesting a potential upside of 292.82%. Given Eledon Pharmaceuticals' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than SELLAS Life Sciences Group.
17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 1.6% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Eledon Pharmaceuticals received 16 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 72.22% of users gave Eledon Pharmaceuticals an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote.
Eledon Pharmaceuticals' return on equity of -45.60% beat SELLAS Life Sciences Group's return on equity.
Summary
Eledon Pharmaceuticals beats SELLAS Life Sciences Group on 9 of the 14 factors compared between the two stocks.
Get SELLAS Life Sciences Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SELLAS Life Sciences Group Competitors List
Related Companies and Tools
